Back

LDL-Cholesterol levels and lipid lowering therapy in secondary prevention patients: preliminary data from BRING-UP Prevention Study

1 September 2024 (13:45 - 13:57)
Organised by: Logo
Congress Presentation Part of: Registries, observational, and other studies on lipids Secondary Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Aldo Pietro Maggioni

Heart Care Foundation, Florence (Italy)

5 More presentations in this session

Presentation thumbnail
Suboptimal Lipid Measurement and Statin Use after Percutaneous Coronary Intervention is associated with Increased Mortality: Results of a Real World Registry of 76,264 Patients in NW London
Doctor M. Akhtar (London, GB)
Slides Video
Presentation thumbnail
Intensive, early and sustained lowering of atherogenic lipoproteins after myocardial infarction and long-term prognosis: a nationwide cohort study of myocardial infarction patients
Ms J. Schubert (Uppsala, SE)
Slides Video
Presentation thumbnail
Association of early versus late use of combination lipid-lowering therapy with major cardiovascular outcomes after myocardial infarction: data from the SWEDEHEART registry
Associate Professor M. Leosdottir (Malmo, SE)
Slides Video
Presentation thumbnail
A global perspective of Lp(a) levels in patients with coronary heart disease - Implications for risk factor control & future trials from the INTERASPIRE Study
Professor K. Ray (London, GB)
Slides Video
Presentation thumbnail
Optimising oral lipid-lowering therapy regimens in high and very high-risk statin intolerant patients with dyslipidaemia: A French real-world simulation
Professor F. Schiele (Besancon, FR)
Slides Video

Access the full session

Session thumbnail
Registries, observational, and other studies on lipids
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 13:45 CET
You may be interested in
thumbnail
Congress Session
Registries, observational, and other studies on lipids
thumbnail
Congress Session
Improving pharmacotherapy in primary prevention
thumbnail
Congress Session
Late-Breaking Clinical Trials: cardiovascular risk and prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources